Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy.

ABSTRACT:

Importance

Metastases-directed stereotactic radiotherapy (SRT) is increasingly performed in patients with metastatic or oligometastatic cancer treated with immune checkpoint inhibitors (ICIs), monoclonal antibodies (mAbs), and small-molecule drugs (SMs). However, little is known about potential interactions between SRT and biological cancer therapy (BCT).

Objective

To prospectively investigate adverse events associated with SRT combined with concurrent BCT.

Design, setting, and participants

This international, prospective, multicenter, noninterventional registry cohort study (Toxicity and Efficacy of Combined Stereotactic Radiotherapy and Systemic Targeted or Immune Therapy [TOaSTT]) was conducted between July 2017 and August 2019 with a 24-month follow-up. Patients f

SUBMITTER: Looman EL 

PROVIDER: S-EPMC12805445 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature